- Home
- PYN vs SRZN Comparison
PYN vs SRZN Comparison
Compare PYN & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYN
- SRZN
- Stock Information
- Founded
- PYN 2002
- SRZN 2015
- Country
- PYN United States
- SRZN United States
- Employees
- PYN N/A
- SRZN N/A
- Industry
- PYN Investment Managers
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- PYN Finance
- SRZN Health Care
- Exchange
- PYN Nasdaq
- SRZN Nasdaq
- Market Cap
- PYN 34.5M
- SRZN 38.1M
- IPO Year
- PYN N/A
- SRZN N/A
- Fundamental
- Price
- PYN $5.74
- SRZN $12.08
- Analyst Decision
- PYN
- SRZN Strong Buy
- Analyst Count
- PYN 0
- SRZN 1
- Target Price
- PYN N/A
- SRZN $45.00
- AVG Volume (30 Days)
- PYN 19.9K
- SRZN 53.7K
- Earning Date
- PYN 01-01-0001
- SRZN 11-06-2024
- Dividend Yield
- PYN 5.07%
- SRZN N/A
- EPS Growth
- PYN N/A
- SRZN N/A
- EPS
- PYN N/A
- SRZN N/A
- Revenue
- PYN N/A
- SRZN $10,000,000.00
- Revenue This Year
- PYN N/A
- SRZN N/A
- Revenue Next Year
- PYN N/A
- SRZN N/A
- P/E Ratio
- PYN N/A
- SRZN N/A
- Revenue Growth
- PYN N/A
- SRZN N/A
- 52 Week Low
- PYN $4.84
- SRZN $6.00
- 52 Week High
- PYN $6.60
- SRZN $18.17
- Technical
- Relative Strength Index (RSI)
- PYN 46.37
- SRZN 50.51
- Support Level
- PYN $5.54
- SRZN $10.20
- Resistance Level
- PYN $5.79
- SRZN $12.51
- Average True Range (ATR)
- PYN 0.05
- SRZN 2.03
- MACD
- PYN 0.01
- SRZN -0.29
- Stochastic Oscillator
- PYN 80.00
- SRZN 24.91
About PYN PIMCO New York Municipal Income Fund III of Beneficial Interest
PIMCO New York Municipal Income Fund III is a closed-end management investment company. Its investment objective is to seek to provide current income exempt from federal, New York State, and New York City income tax. To pursue the objectives, the fund invests a majority of its net assets in municipal bonds that pay interest that is exempt from federal, New York State, and New York City income tax.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).